Day 1 · Training
Wed 16 Sep- Introduction to VAMs / 505(b)(2)
- Regulatory & clinical — US and EU
- Non-clinical & bridging strategy
- IP & patent challenges
- Business strategy & market access
- Round table: country pricing & reimbursement
16–17 September 2026 · Barcelona
HYBRIDGE
The first conference for industry Value-Added Medicines and 505(b)(2). From early ideation to market — under one roof.
Organised by Annion Pharma
2 days · 25 sessions 12 confirmed speakers End-to-end US ↔ EU
Why HYBRIDGE
There is no industry-run, end-to-end, US ↔ EU conference dedicated to Value-Added Medicines and 505(b)(2). HYBRIDGE owns that white space.
End-to-end scope
Ideation, IP, non-clinical, clinical, regulatory (US + EU), market access, BD and licensing — all in two days.
Industry voices
Operators from Bluepharma, Polpharma, Adalvo, Nanomol, Galenicap, Valdiano — not vendor sales decks.
A working network
Intentionally intimate (~50 attendees), no exhibition-hall noise — every conversation matters.
Programme at a glance
See the full agenda →Day 2 · Industry experience
Thu 17 Sep- Value proposition & commercial strategy
- Technologies: solid-form, nanomedicine, biologics, lyo, repurposing
- Round table: portfolio selection
- The Bluepharma experience
- Bridging EMA and FDA
- Round table: licensing VAMs
Featured speakers
See all speakers →AG
Ana Gavaldá
AnnionAC
Ana Caterina Pinto
BluepharmaRD
Rosanne d'Alessio
ValdianoCR
Carlos Rodriguez
PolpharmaJB
James Burt
ProductLifeHP
Hans Platteeuw
Galenicap / NeuraxpharmTS
Toni Santamaria
AdalvoIC
Irene Casalprim
AdalvoVP
Victor Perez
SolitekWhy attend
What you'll leave with
Two days end-to-end, designed so you walk out with a working playbook and the network to execute it — not a folder of slide decks you'll never re-open.
A development-to-market playbook
Two days mapped end-to-end: ideation, IP, non-clinical, clinical, regulatory (US + EU), market access, BD and licensing — finally in one place.
Real industry experience
Operators from Bluepharma, Polpharma, Adalvo, Nanomol, Galenicap and Valdiano share what actually worked — and what they would have done differently.
US + EU clarity in one place
Dual regulatory and clinical perspective from speakers active in both markets. Saves you the budget and time of attending two separate conferences.
A working network you can call
Intentionally intimate — ~50 senior attendees, no exhibition-hall noise. The people you meet on day 1 are the ones you call when you hit a roadblock six months later.
Frameworks for portfolio selection
Round-table sessions on which 505(b)(2) assets are worth pursuing — with the executives who make those calls for a living.
The BD lens on VAMs
What investors, licensors and acquirers actually look for — directly from those who package, pitch and value these programmes.
Made for portfolio leads, regulatory affairs, business development and R&D heads working on Value-Added Medicines and 505(b)(2) programmes.
Venue
Two days in Barcelona
Hosted in the centre of Barcelona — a pharma cluster with strong connections to both EU and US markets. The evening networking event is the moment most attendees remember a year later.
FAQ
Frequently asked questions
Quick answers to the most common questions. Don't see yours? Get in touch .
Where and when is HYBRIDGE 2026?▸
16–17 September 2026, in Barcelona. Venue announced to confirmed attendees one month before the event.
Who should attend?▸
Mid-to-senior professionals in pharma working on Value-Added Medicines and 505(b)(2) — portfolio leads, regulatory affairs, business development, R&D heads, market access, and CDMOs supporting these programmes.
Is the conference in English?▸
Yes — all sessions, materials and round-table discussions are in English.
What does the ticket include?▸
Access to all sessions across both days, lunch and coffee breaks, the evening networking event on 16 September, and the full programme materials.
How is the group discount applied?▸
Register two or more delegates from the same company in one submission and the per-seat price drops automatically to €1,530 (15% off the standard rate). No code needed.
When does the early bird end?▸
Early-bird pricing (€1,620 / 10% off) is available until 30 July 2026. After that, single tickets are €1,800.
Can I cancel or transfer my ticket?▸
Yes — see the cancellation terms in our terms of use. Substituting one named attendee for another is free up to 7 days before the event.
How do I pay?▸
After you submit the registration form we email you an invoice with bank-transfer instructions. If your company pays by purchase order or net terms, choose “Invoice” at checkout and our team will follow up.
Tickets
Register →Early bird
€1,620
10% off · before 30 Jul
Standard
€1,800
Single delegate
2+ delegates
€1,530
15% off · per seat
All tiers include lunch, coffee breaks and the networking event.
Sponsorship
Sponsor packages →Founding sponsors get unmatched visibility with the buying committee on both sides of the Atlantic. Three tiers — Supporting, Industry and Strategic Partner — each designed for a different commercial goal.
Supporting PartnerIndustry PartnerStrategic Partner
Founding sponsors
Nanomol-techFarmaprojectsBCNlifesciences Your logo here →
The VAMs Briefing
A monthly 5-minute read on what's moving in VAMs and 505(b)(2)
One regulatory or market signal · one operator story · one numbers panel. Unsubscribe anytime.
Questions about the programme or sponsorship?
We come back within one business day.